Država: Kanada
Jezik: angleščina
Source: Health Canada
CEFTRIAXONE (CEFTRIAXONE SODIUM)
TEVA CANADA LIMITED
J01DD04
CEFTRIAXONE
1G
POWDER FOR SOLUTION
CEFTRIAXONE (CEFTRIAXONE SODIUM) 1G
INTRAMUSCULAR
4ML(REGULAR)/2.8ML(LOW VOLUME)
Prescription
THIRD GENERATION CEPHALOSPORINS
Active ingredient group (AIG) number: 0117292003; AHFS:
APPROVED
2006-11-02
_PAGE 1 OF 58 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr CEFTRIAXONE SODIUM FOR INJECTION (STERILE CEFTRIAXONE SODIUM) STERILE POWDER FOR SOLUTION, 1 G AND 10 G CEFTRIAXONE PER VIAL, INTRAVENOUS OR INTRAMUSCULAR BP ANTIBIOTIC TEVA CANADA LIMITED 30 NOVOPHARM COURT TORONTO, ONTARIO M1B 2K9 CONTROL NO: 246728 DATE OF INITIAL AUTHORIZATION: NOV. 02, 2006 DATE OF REVISION: MAY 26, 2021 _PAGE 2 OF 58 _ RECENT MAJOR LABEL CHANGES WARNINGS AND PRECAUTIONS 04/2020 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. Table of Contents RECENT MAJOR LABEL CHANGES ..................................................................................... 2 TABLE OF CONTENTS .......................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION............................................................... 4 1. INDICATIONS............................................................................................................... 4 1.1 PEDIATRICS..................................................................................................................... 5 1.2 GERIATRICS ..................................................................................................................... 5 2. CONTRAINDICATIONS ................................................................................................ 5 4. DOSAGE AND ADMINISTRATION ............................................................................... 5 4.1 DOSING CONSIDERATIONS ................................................................................................ 5 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT............................................................ 5 4.3 RECONSTITUTION .............................................................................................................. 7 4.4 ADMINISTRATION.................................................................................. Preberite celoten dokument